Form D · Pharmaceuticals
Nivagen Pharmaceuticals, Inc.
Sacramento, CA · CIK 0001716747
Offering snapshot reported Aug 11, 2023 · SEC filing
- Reported sold
- $5M Offering amount: $5M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jun 16, 2023 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 11, 2023 | Initial | $5,000,005 | No comparison | 1 | SEC filing |
| May 20, 2020 | Initial | $15,966,462 | No comparison | 7 | SEC filing |
| Sep 14, 2017 | Initial | $10,000,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-489503
Source: Form D, filed Aug 11, 2023. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Sharad Dadbhawala | Director |
| Praneel Deo | Executive |
| Rob C. Hart | Director |
| Michael Kulper | Director |
| Dasaradhi Lakkaraju | Executive |
| Jaswinder Matharu | Director |
| Gopal Patel | Executive |
| Ashish Sevak | Director |
| Jwalant Shukla | Director, Executive |
| Bikramjit Singh | Director |
| Bikram Singh | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
3100 Fite Circle Suite 100
Sacramento, CA, 95827
Sacramento, CA, 95827